Cingulate (CINGW) Accumulated Expenses (2021 - 2026)
Cingulate's (CINGW) quarterly Accumulated Expenses came in at $1.3 million in Q2 2026, up 163.57% on a YoY basis from $501786.0 in Q2 2025, and down 24.08% quarter-over-quarter from $1.7 million in Q4 2025.
Analysis
Cingulate (CINGW) Accumulated Expenses (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Accumulated Expenses for 6 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Accumulated Expenses rose 163.57% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 million (up 163.57% YoY), and the FY2025 full-year result was $1.7 million, up 67.57% from the prior year.
- Accumulated Expenses fell to $1.3 million in Q2 2026 per CINGW's latest filing, from $1.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.7 million in Q4 2025 and bottomed at $311573.0 in Q2 2022.
- Historically, Accumulated Expenses has averaged $906178.3 across 5 years, with a median of $756035.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 62.36% in 2024, then soared 297.9% in 2025.
- Over 5 years, Accumulated Expenses stood at $894635.0 in 2022, then jumped by 84.6% to $1.7 million in 2023, then plunged by 37.05% to $1.0 million in 2024, then jumped by 67.57% to $1.7 million in 2025, then declined by 24.08% to $1.3 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $1.3 million, $1.7 million, and $1.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.32 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 501,786.00 |
| Mar 31, 2025 | 601,840.00 |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 402,152.00 |
| Jun 30, 2024 | 383,313.00 |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 692,008.00 |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 699,182.00 |
| Dec 31, 2022 | 894,635.00 |
| Sep 30, 2022 | 670,651.00 |
| Jun 30, 2022 | 311,573.00 |
| Mar 31, 2022 | 756,035.00 |
| Dec 31, 2021 | 601,300.00 |